A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sumitomo to Cut Med- to Long-Term Guidance amid Tepid Uptake of New Drivers
February 1, 2024
-
REGULATORY Japan to Revise Ad Guidelines to Address GLP-1 Use for Cosmetic Weight Loss
January 31, 2024
-
COMMENTARY Is Case of Leqembi a “Steppingstone” to New CEA Price Adjustment Rule? Pharma Industry on Guard
January 30, 2024
-
REGULATORY MHLW to Require Pharma to Disclose More Categories of Physician Payments under Clinical Trials Act
January 30, 2024
-
REGULATORY Chuikyo to Discuss Exclusion of Long-Listed Biologics from New Coverage Scheme
January 29, 2024
-
REGULATORY Break-Up of LDP Factions Won’t Have Major Impact on Pharma Policy, but Could Make Lobbying Tougher
January 26, 2024
-
BUSINESS Towa Begins Priority Supply of 23 APIs, Mostly under Shipment Curbs, to Quake-Hit Area
January 26, 2024
-
ORGANIZATION JGA Chief Wary of “Full” Off-Year Revision in 2025, Urges Broader Exemptions If Plan Goes Forward
January 25, 2024
-
BUSINESS Ono Revs Up to Boost Global Presence, Launches New HR Scheme
January 24, 2024
-
COMMENTARY Goals of the “Innovation Box” Tax Break in FY2024 Reform
January 23, 2024
-
ACADEMIA Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi
January 22, 2024
-
BUSINESS LEO Pharma Poised to Build Presence in Japan as Dermatology Leader: CEO
January 19, 2024
-
REGULATORY Market Expansion Re-Pricing to Hit 23 Meds in April, Opdivo Faces Yet Another Cut in Spillover
January 18, 2024
-
BUSINESS Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
-
BUSINESS Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing
January 18, 2024
-
BUSINESS Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November
January 17, 2024
-
REGULATORY MHLW Issues Notification to Clarify Orphan Designation Criteria
January 17, 2024
-
COMMENTARY Introduction of Elective Care to Mark Watershed for Long-Listed Drug Makers
January 17, 2024
-
REGULATORY FY2024 Reform Will Bolster Rewards for Innovation to Eradicate Drug Lag/Loss: LDP Policy Bigwig
January 16, 2024
-
REGULATORY New LLP Coverage Rule Aimed to Transform Industry Rather Than Eke Out Savings: LDP Social Security Chief
January 15, 2024
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…